ADC Therapeutics Reports Strong Q4 Revenue, Positive LOTIS-7 Data, and Extends Cash Runway into 2028
Summary
ADC Therapeutics reported fourth quarter and full year 2025 financial results, showing increased net product revenue of $22.3 million for Q4 and $73.6 million for the full year. Critically, the company announced a robust cash position of $261.3 million as of December 31, 2025, providing an expected cash runway at least into 2028. Operationally, the LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with glofitamab in relapsed or refractory DLBCL demonstrated highly positive interim data with an 89.8% overall response rate and a 77.6% complete response rate. Additionally, topline data for the pivotal LOTIS-5 Phase 3 confirmatory trial is anticipated in the second quarter of 2026, representing a significant near-term catalyst. This combination of financial stability and strong clinical progress is highly material for a commercial-stage biotech.
At the time of this announcement, ADCT was trading at $4.23 on NYSE in the Life Sciences sector, with a market capitalization of approximately $524M. The 52-week trading range was $1.05 to $4.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.